{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:47:30Z","timestamp":1794646050234,"version":"4.9.1"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.canlet.2025.218185","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:20:55Z","timestamp":1764634855000},"page":"218185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Updated clinical practice guidelines for the management of adult diffuse gliomas"],"prefix":"10.1016","volume":"640","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7008-6351","authenticated-orcid":false,"given":"Tao","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Hyun","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvi","family":"Ram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai-sang","family":"Poo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiguang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damdindorj","family":"Boldbaatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanlu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Tergaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunsheng","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmin","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anhua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggao","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Sai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinting","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengqing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dezhi","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanbao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoshi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gan","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoshi","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanzhang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruichao","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinquan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.218185_bib1","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib2","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1474-4422(18)30468-X","article-title":"Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the global burden of disease study 2016","volume":"18","author":"Brain","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.canlet.2025.218185_bib3","first-page":"203","article-title":"Cancer survival statistics in China 2019-2021: a multicenter, population-based study","volume":"4","author":"Zeng","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"10.1016\/j.canlet.2025.218185_bib4","first-page":"221","article-title":"Cancer incidence and mortality in China, 2022","volume":"46","author":"Zheng","year":"2024","journal-title":"Zhonghua Zhongliu Zazhi"},{"key":"10.1016\/j.canlet.2025.218185_bib5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.canlet.2016.01.024","article-title":"Glioma cooperative, CGCG clinical practice guidelines for the management of adult diffuse gliomas","volume":"375","author":"Jiang","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218185_bib6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11060-013-1103-9","article-title":"Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution","volume":"113","author":"Yang","year":"2013","journal-title":"Journal of neuro-oncology"},{"key":"10.1016\/j.canlet.2025.218185_bib7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12880-024-01274-9","article-title":"Structural- and DTI- MRI enable automated prediction of IDH mutation status in CNS WHO grade 2-4 glioma patients: a deep radiomics approach","volume":"24","author":"Yuan","year":"2024","journal-title":"BMC Med. Imag."},{"key":"10.1016\/j.canlet.2025.218185_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.998069","article-title":"Alterations in white matter fiber density associated with structural MRI and metabolic PET lesions following multimodal therapy in glioma patients","volume":"12","author":"Friedrich","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib9","article-title":"Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China","volume":"7","author":"Yan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2025.218185_bib10","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218185_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00432-013-1519-9","article-title":"Correlation of IDH1\/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China","volume":"140","author":"Zhang","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib12","article-title":"Isocitrate dehydrogenase 1 gene mutation is associated with prognosis in clinical low-grade gliomas","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2025.218185_bib13","doi-asserted-by":"crossref","first-page":"9852","DOI":"10.1158\/0008-5472.CAN-06-1796","article-title":"A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma","volume":"66","author":"Jenkins","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.218185_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/neuonc\/nor185","article-title":"Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China","volume":"14","author":"Li","year":"2012","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib15","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ana.20543","article-title":"Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas","volume":"58","author":"Kujas","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.canlet.2025.218185_bib16","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1200\/JCO.2009.23.6497","article-title":"NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide","volume":"27","author":"Wick","year":"2009","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.canlet.2025.218185_bib17","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1126\/science.aaf2666","article-title":"An anatomic transcriptional atlas of human glioblastoma","volume":"360","author":"Puchalski","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.canlet.2025.218185_bib18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00401-013-1156-z","article-title":"ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis","volume":"126","author":"Wiestler","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.canlet.2025.218185_bib19","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41467-024-44932-w","article-title":"Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas","volume":"15","author":"Hariharan","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.218185_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00401-018-1849-4","article-title":"Novel, improved grading system(s) for IDH-mutant astrocytic gliomas","volume":"136","author":"Shirahata","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.canlet.2025.218185_bib21","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/neuonc\/noz126.000","article-title":"CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas","volume":"21","author":"Appay","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11060-020-03528-2","article-title":"The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature","volume":"148","author":"Lu","year":"2020","journal-title":"Journal of neuro-oncology"},{"key":"10.1016\/j.canlet.2025.218185_bib23","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","article-title":"Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors","volume":"372","author":"Eckel-Passow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218185_bib24","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1038\/bjc.2014.538","article-title":"TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations","volume":"111","author":"Labussiere","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2025.218185_bib25","doi-asserted-by":"crossref","first-page":"24871","DOI":"10.18632\/oncotarget.4549","article-title":"TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2025.218185_bib26","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib27","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00401-018-1913-0","article-title":"cIMPACT-NOW update 3: recommended diagnostic criteria for \"Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV\"","volume":"136","author":"Brat","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.canlet.2025.218185_bib28","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.218185_bib29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0028-3843(14)60408-4","article-title":"The role of the PTEN gene in malignant gliomas","volume":"44","author":"Alexiou","year":"2010","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.canlet.2025.218185_bib30","article-title":"Clinical roles of EGFR amplification in diffuse gliomas: a real-world study using the 2021 WHO classification of CNS tumors","volume":"18","author":"Wang","year":"2024","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.canlet.2025.218185_bib31","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.218185_bib32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/neuonc\/noab231","article-title":"The EGFRvIII transcriptome in glioblastoma: a meta-omics analysis","volume":"24","author":"Hoogstrate","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib33","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2010.28.6963","article-title":"Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma","volume":"28","author":"Sampson","year":"2010","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.canlet.2025.218185_bib34","article-title":"Prognostic value of O (6)-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas","volume":"4","author":"Lam","year":"2022","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.canlet.2025.218185_bib35","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218185_bib36","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/cncr.27826","article-title":"Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme","volume":"119","author":"Zhang","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2025.218185_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40478-024-01817-9","article-title":"A multi-institutional series of a novel, recurrent TRIM24::MET fusion-driven infant-type hemispheric glioma reveals significant clinico-pathological heterogeneity","volume":"12","author":"Gorodezki","year":"2024","journal-title":"Acta neuropathologica communications"},{"key":"10.1016\/j.canlet.2025.218185_bib38","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1097\/CM9.0000000000002446","article-title":"Molecular pathology and clinical implications of diffuse glioma","volume":"135","author":"Chai","year":"2022","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.canlet.2025.218185_bib39","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.13198","article-title":"MET fusions and splicing variants is a strong adverse prognostic factor in astrocytoma, isocitrate dehydrogenase mutant","volume":"34","author":"Liu","year":"2024","journal-title":"Brain Pathol."},{"key":"10.1016\/j.canlet.2025.218185_bib40","article-title":"RANO 2.0: update to the response assessment in neuro-oncology criteria for High- and low-grade gliomas in adults","author":"Wen","year":"2023","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.canlet.2025.218185_bib41","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s00330-004-2565-0","article-title":"Cortical mapping by functional magnetic resonance imaging in patients with brain tumors","volume":"15","author":"Majos","year":"2005","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.canlet.2025.218185_bib42","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11060-010-0193-x","article-title":"Surgical treatment of high-grade gliomas in motor areas. The impact of different supportive technologies: a 171-patient series","volume":"100","author":"Talacchi","year":"2010","journal-title":"Journal of neuro-oncology"},{"key":"10.1016\/j.canlet.2025.218185_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080916","article-title":"Supratentorial gliomas in eloquent areas: which parameters can predict functional outcome and extent of resection?","volume":"8","author":"Spena","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2025.218185_bib44","doi-asserted-by":"crossref","first-page":"E124","DOI":"10.1093\/neuros\/nyz441","article-title":"A novel sequence: ZOOMit-Blood oxygen level-dependent for motor-cortex localization","volume":"86","author":"Fang","year":"2020","journal-title":"Neurosurgery"},{"key":"10.1016\/j.canlet.2025.218185_bib45","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3174\/ajnr.A5342","article-title":"Anatomic location of tumor predicts the accuracy of motor function localization in diffuse lower-grade gliomas involving the hand knob area","volume":"38","author":"Fang","year":"2017","journal-title":"AJNR. American journal of neuroradiology"},{"key":"10.1016\/j.canlet.2025.218185_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.bandl.2019.104741","article-title":"Spatiotemporal dynamics of postoperative functional plasticity in patients with brain tumors in language areas","volume":"202","author":"Lizarazu","year":"2020","journal-title":"Brain Lang."},{"key":"10.1016\/j.canlet.2025.218185_bib47","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00062-015-0496-6","article-title":"Post-surgical language reorganization occurs in tumors of the dominant and non-dominant hemisphere","volume":"27","author":"Avramescu-Murphy","year":"2017","journal-title":"Clin. Neuroradiol."},{"key":"10.1016\/j.canlet.2025.218185_bib48","doi-asserted-by":"crossref","first-page":"84587","DOI":"10.18632\/oncotarget.13139","article-title":"FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2025.218185_bib49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41016-020-00198-x","article-title":"Role of molecular biomarkers in glioma resection: a systematic review","volume":"6","author":"Li","year":"2020","journal-title":"Chin Neurosurg J"},{"key":"10.1016\/j.canlet.2025.218185_bib50","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41698-021-00205-z","article-title":"Quantitative MRI-based radiomics for noninvasively predicting molecular subtypes and survival in glioma patients","volume":"5","author":"Yan","year":"2021","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib51","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41586-023-06615-2","article-title":"Ultra-fast deep-learned CNS tumour classification during surgery","volume":"622","author":"Vermeulen","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.218185_bib52","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1227\/neu.0000000000002260","article-title":"Application of intraoperative rapid molecular diagnosis in precision surgery for glioma: mimic the world health organization CNS5 integrated diagnosis","volume":"92","author":"Xue","year":"2023","journal-title":"Neurosurgery"},{"key":"10.1016\/j.canlet.2025.218185_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104899","article-title":"Rapid intraoperative multi-molecular diagnosis of glioma with ultrasound radio frequency signals and deep learning","volume":"98","author":"Xie","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2025.218185_bib54","doi-asserted-by":"crossref","DOI":"10.1007\/s11060-018-2985-3","article-title":"The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study","author":"Ding","year":"2018","journal-title":"Journal of neuro-oncology"},{"key":"10.1016\/j.canlet.2025.218185_bib55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10014-018-0324-1","article-title":"A surgical strategy for lower grade gliomas using intraoperative molecular diagnosis","volume":"35","author":"Koriyama","year":"2018","journal-title":"Brain Tumor Pathol."},{"key":"10.1016\/j.canlet.2025.218185_bib56","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00701-015-2621-3","article-title":"Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up","volume":"158","author":"Duffau","year":"2016","journal-title":"Acta Neurochir."},{"key":"10.1016\/j.canlet.2025.218185_bib57","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.neuchi.2016.09.006","article-title":"Supratotal resection of diffuse gliomas - an overview of its multifaceted implications","volume":"63","author":"Yordanova","year":"2017","journal-title":"Neurochirurgie"},{"key":"10.1016\/j.canlet.2025.218185_bib58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3171\/2011.2.JNS10998","article-title":"An extent of resection threshold for newly diagnosed glioblastomas","volume":"115","author":"Sanai","year":"2011","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.canlet.2025.218185_bib59","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3171\/2008.4.17536","article-title":"Independent association of extent of resection with survival in patients with malignant brain astrocytoma","volume":"110","author":"McGirt","year":"2009","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.canlet.2025.218185_bib60","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaoncol.2019.6143","article-title":"Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma","volume":"6","author":"Molinaro","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib61","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-Mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218185_bib62","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218185_bib63","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.canlet.2025.218185_bib64","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1200\/JCO.2008.20.7944","article-title":"Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma","volume":"27","author":"Clarke","year":"2009","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.canlet.2025.218185_bib65","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218185_bib66","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218185_bib67","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa065901","article-title":"Radiotherapy for glioblastoma in the elderly","volume":"356","author":"Keime-Guibert","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218185_bib68","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.2004.06.082","article-title":"Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial","volume":"22","author":"Roa","year":"2004","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.canlet.2025.218185_bib69","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2025.218185_bib70","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/j.clon.2023.01.012","article-title":"Metronomic temozolomide in heavily pretreated patients with recurrent isocitrate dehydrogenase wild-type glioblastoma: a large real-life mono-institutional study","volume":"35","author":"Bosio","year":"2023","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib71","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-14-2737","article-title":"MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial","volume":"21","author":"Weller","year":"2015","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.canlet.2025.218185_bib72","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2407-10-30","article-title":"BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors","volume":"10","author":"Reithmeier","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2025.218185_bib73","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/neuonc\/noz222","article-title":"INTELLANCE 2\/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma","volume":"22","author":"Van Den Bent","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib74","article-title":"Efficacy and safety study of fotemustine and bevacizumab in patients with recurrent glioblastoma","volume":"40","author":"Escudero","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib75","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and Bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218185_bib76","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1016\/S1470-2045(17)30345-5","article-title":"European association for neuro-oncology (EANO) guidelines for palliative care in adults with glioma","volume":"18","author":"Pace","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/neuonc\/noad154","article-title":"Brain tumor-related epilepsy management: a society for Neuro-oncology (SNO) consensus review on current management","volume":"26","author":"Avila","year":"2024","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib78","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/nop\/npv038","article-title":"Seizures and cancer: drug interactions of anticonvulsants with chemotherapeutic agents, tyrosine kinase inhibitors and glucocorticoids","volume":"3","author":"Benit","year":"2016","journal-title":"Neuro-Oncol. Pract."},{"key":"10.1016\/j.canlet.2025.218185_bib79","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/epi.16880","article-title":"First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid","volume":"62","author":"van der Meer","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.canlet.2025.218185_bib80","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archneurol.2009.335","article-title":"Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study","volume":"67","author":"Rosati","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.canlet.2025.218185_bib81","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3747\/co.v13i6.107","article-title":"The use of prophylactic anticonvulsants in patients with brain tumours-a systematic review","volume":"13","author":"Perry","year":"2006","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib82","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/brain\/aww046","article-title":"Corticosteroids compromise survival in glioblastoma","volume":"139","author":"Pitter","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.canlet.2025.218185_bib83","article-title":"Perioperative corticosteroid treatment impairs tumor-infiltrating dendritic cells in patients with newly diagnosed adult-type diffuse gliomas","volume":"13","author":"Carenza","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2025.218185_bib84","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 4","key":"10.1016\/j.canlet.2025.218185_bib85","doi-asserted-by":"crossref","first-page":"iv73","DOI":"10.1093\/neuonc\/nos197","article-title":"Thromboembolic disease in patients with high-grade glioma","volume":"14","author":"Perry","year":"2012","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib86","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3041824","article-title":"Cognitive rehabilitation in patients with gliomas and other brain tumors: state of the art","volume":"2016","author":"Bergo","year":"2016","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.canlet.2025.218185_bib87","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1200\/JCO.2017.72.7511","article-title":"Response assessment in neuro-oncology clinical trials","volume":"35","author":"Wen","year":"2017","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.canlet.2025.218185_bib88","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","article-title":"Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas","volume":"9","author":"Brandsma","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib89","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.canlet.2025.218185_bib90","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41392-023-01637-8","article-title":"From signalling pathways to targeted therapies: unravelling glioblastoma's secrets and harnessing two decades of progress","volume":"8","author":"Dewdney","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2025.218185_bib91","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/neuonc\/noac096","article-title":"Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma","volume":"24","author":"Rosenberg","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib92","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMcibr1309402","article-title":"Angiogenesis in glioblastoma","volume":"369","author":"Das","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218185_bib93","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2025.218185_bib94","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/ijc.2910590415","article-title":"Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms","volume":"59","author":"Plate","year":"1994","journal-title":"International journal of cancer. Journal international du cancer"},{"key":"10.1016\/j.canlet.2025.218185_bib95","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2015.63.4691","article-title":"Bevacizumab plus irinotecan versus temozolomide in newly diagnosed O6-Methylguanine-DNA methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial","volume":"34","author":"Herrlinger","year":"2016","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.canlet.2025.218185_bib96","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/neuonc\/noab011","article-title":"Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG\/RTOG 0825)","volume":"23","author":"Wefel","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib97","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","article-title":"Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"20","author":"Lombardi","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib98","first-page":"855","article-title":"The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma","volume":"123","author":"Parker","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2025.218185_bib99","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1126\/science.1220834","article-title":"Transforming fusions of FGFR and TACC genes in human glioblastoma","volume":"337","author":"Singh","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.canlet.2025.218185_bib100","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/neuonc\/noaa121","article-title":"Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions","volume":"22","author":"Di Stefano","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib101","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1158\/1078-0432.CCR-21-2664","article-title":"Infigratinib in patients with recurrent gliomas and FGFR alterations: a multicenter phase II study","volume":"28","author":"Lassman","year":"2022","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.canlet.2025.218185_bib102","article-title":"Cancer genome consortium PedBrain tumor, recurrent MET fusion genes represent a drug target in pediatric glioblastoma","author":"International","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.218185_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.09.038","article-title":"Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor","author":"Hu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.218185_bib104","doi-asserted-by":"crossref","DOI":"10.1101\/gr.165126.113","article-title":"RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas","author":"Bao","year":"2014","journal-title":"Genome Res."},{"key":"10.1016\/j.canlet.2025.218185_bib105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s41016-023-00329-0","article-title":"PTPRZ1-METFUsion GENe (ZM-FUGEN) trial: study protocol for a multicentric, randomized, open-label phase II\/III trial","volume":"9","author":"Bao","year":"2023","journal-title":"Chin Neurosurg J"},{"key":"10.1016\/j.canlet.2025.218185_bib106","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.canlet.2025.218185_bib107","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pharmthera.2015.05.003","article-title":"Metabolic consequences of oncogenic IDH mutations","volume":"152","author":"Parker","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.canlet.2025.218185_bib108","article-title":"Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity","volume":"10","author":"Cai","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.canlet.2025.218185_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(25)00472-3","article-title":"Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial","author":"Cloughesy","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib110","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1158\/1078-0432.CCR-18-1140","article-title":"Rindopepimut with Bevacizumab for patients with relapsed EGFRvIII-Expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial","volume":"26","author":"Reardon","year":"2020","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.canlet.2025.218185_bib111","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218185_bib112","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1196310","article-title":"Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma","volume":"5","author":"Wang","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2025.218185_bib113","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1541535","article-title":"PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor","volume":"8","author":"Wang","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2025.218185_bib114","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.218185_bib115","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-Cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218185_bib116","first-page":"2554","article-title":"CAR-armed cell therapy for gliomas","volume":"9","author":"Zhai","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218185_bib117","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03451-3","article-title":"Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial","author":"Vitanza","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.218185_bib118","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41698-024-00506-z","article-title":"Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma","volume":"8","author":"Chiavelli","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib119","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/neuonc\/noy032","article-title":"CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges","volume":"20","author":"Bagley","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2025.218185_bib120","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525007578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525007578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:07:49Z","timestamp":1779116869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525007578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":120,"alternative-id":["S0304383525007578"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218185","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updated clinical practice guidelines for the management of adult diffuse gliomas","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218185"}}